Welcome to our dedicated page for TRACON PHARMS news (Ticker: TCON), a resource for investors and traders seeking the latest updates and insights on TRACON PHARMS stock.
TRACON Pharmaceuticals, Inc. (symbol: TCON) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapeutics for the treatment of cancer and wet age-related macular degeneration (AMD). The firm's leading clinical-stage product is Envafolimab (KN035), an investigational PD-L1 single-domain antibody designed for the treatment of soft tissue sarcoma.
The company's portfolio also includes:
- DE-122: Currently in a randomized Phase IIa study targeting wet AMD.
- TRC102: A small molecule in Phase II clinical trials for mesothelioma, Phase I trials for solid tumors, and additional trials for lymphomas and lung cancer.
- TRC253: In Phase II clinical trials for treating metastatic castration-resistant prostate cancer.
- TJ004309: A CD73 antibody in Phase I development for solid tumors.
TRACON Pharmaceuticals operates on a cost-efficient, contract research organization (CRO)-independent product development platform. This unique approach allows the company to partner with ex-U.S. companies, facilitating the development and commercialization of innovative therapies within the United States.
The company's collaborative efforts and licensing agreements with other firms reinforce its commitment to delivering cutting-edge treatments. Financially, TRACON demonstrates resilience and strategic growth, leveraging partnerships to advance their clinical trials and ensure a pipeline of promising therapeutic candidates.
For investors, TRACON Pharmaceuticals represents a significant opportunity in the biopharmaceutical landscape, driven by a robust pipeline of investigational drugs and a strategic focus on effective, targeted cancer therapies.
TRACON Pharmaceuticals (TCON) has partnered with Eucure Biopharma for the development of YH001, a CTLA-4 antibody designed for oncology therapies. The agreement assigns TRACON the responsibility for clinical development and commercialization in North America, with Eucure supplying YH001. The antibody shows enhanced ADCC and CDC functions and is currently in multiple Phase 1 trials in Australia and China.
TRACON plans to initiate a Phase 1 trial of YH001 combined with envafolimab for soft tissue sarcoma while studying its use in various tumors, expecting significant cost savings.
TRACON Pharmaceuticals (NASDAQ: TCON) announced a corporate overview presentation by CEO Dr. Charles Theuer at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 20, 2021, at 1:15 PM ET. The company, focused on targeted cancer therapies, is advancing its clinical-stage pipeline including Envafolimab, TRC102, and TJ004309. Access to the presentation webcast is available on their website.
TRACON Pharmaceuticals (NASDAQ: TCON) will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Dr. Charles Theuer, the CEO, will lead the presentation, which will be available on-demand starting at 7:00 AM ET on September 13, 2021, on the company's website. TRACON is focused on developing targeted cancer therapeutics with a cost-efficient, CRO-independent platform, including products like Envafolimab and TRC102. For more details, visit www.traconpharma.com.
TRACON Pharmaceuticals (NASDAQ: TCON) has announced that Dr. Charles Theuer, President and CEO, will present a corporate overview at the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 12:40 PM ET. The company specializes in developing targeted cancer therapies and operates a cost-effective, CRO-independent product development platform. TRACON's pipeline includes Envafolimab, TRC102, and TJ004309, aimed at treating various types of cancer. Interested parties can access the presentation via the company's website.
TRACON Pharmaceuticals (NASDAQ:TCON) reported its Q2 2021 financial results, revealing a net loss of $8.9 million, up from $4.5 million in Q2 2020. Cash and equivalents stood at $25.6 million as of June 30, 2021, not including proceeds from a recent $15 million public offering, extending the cash runway into 2023. The company anticipates interim efficacy data from the ENVASARC trial by year-end 2021, with the Independent Data Monitoring Committee recommending the trial proceed after reviewing safety data.
TRACON Pharmaceuticals (NASDAQ: TCON) announced that the Independent Data Monitoring Committee has recommended the continuation of the ENVASARC pivotal trial following a review of safety data from over 20 patients treated with envafolimab. The trial aims to assess the therapy in refractory sarcoma patients. Envafolimab is a novel PD-L1 inhibitor currently undergoing various trials globally. The company expects interim efficacy data to be reviewed in Q4 2021, after initial promising results with a 32% objective response rate in advanced solid tumor patients.
TRACON Pharmaceuticals (NASDAQ: TCON) will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 12:00 PM ET. The presentation by CEO Charles Theuer, M.D., Ph.D., will highlight the company's focus on developing targeted cancer therapies through a cost-efficient, CRO-independent approach. Key products include Envafolimab for sarcoma, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. For live access, visit the Investors section on TRACON's website.
TRACON Pharmaceuticals (NASDAQ:TCON) will release its Q2 2021 financial results after U.S. markets close on August 11, 2021. The company is focused on developing targeted cancer therapeutics and operates a cost-efficient, CRO-independent platform for partnerships in the U.S. and abroad. A conference call will follow to discuss these results and corporate updates. The company is advancing its clinical pipeline, which includes key products like Envafolimab and TRC102. For further details, visit TRACON's website.
TRACON Pharmaceuticals (TCON) has announced an increase in its public offering to 3,926,702 shares at $3.82 each, aiming for gross proceeds of approximately $15 million. The underwriter, H.C. Wainwright & Co., has also been granted a 30-day option for an additional 589,005 shares. The funds raised will support clinical development of Envafolimab and general corporate purposes. The offering is expected to close around July 26, 2021, pending customary conditions.
TRACON Pharmaceuticals (NASDAQ: TCON) has announced an underwriting agreement with H.C. Wainwright & Co. for the purchase of 2,617,802 shares at $3.82 each, expected to close on July 26, 2021. The gross proceeds are estimated at $10 million, which will support the clinical development of envafolimab and general corporate purposes. Additionally, the underwriter holds a 30-day option to purchase 392,670 additional shares. The offering is conducted under a previously effective registration statement with the SEC.
FAQ
What is the current stock price of TRACON PHARMS (TCON)?
What is the market cap of TRACON PHARMS (TCON)?
What does TRACON Pharmaceuticals specialize in?
What is Envafolimab (KN035)?
What products are in TRACON's clinical pipeline?
What is TRC102 designed to treat?
How does TRACON Pharmaceuticals conduct its product development?
What phase is TRC253 currently in?
What is unique about TRACON's development approach?
Are there any financial highlights for TRACON Pharmaceuticals?
What is DE-122 aimed at treating?
What partnerships does TRACON Pharmaceuticals have?
